VO659, a CAG repeat-targeting antisense oligonucleotide, lowers multiple neurotoxic mutant huntingtin proteins in Huntington's disease

Huntington's disease, a rare and fatal genetic disorder, arises from abnormal expansion of CAG sequences in DNA, resulting in toxic protein accumulation. Professor Vincent Dion of Cardiff University, who led the study, explained that the length of these repeated sequences determines disease severity, making targeted reduction a promising therapeutic approach.

Traditional gene-editing techniques, while effective, can cause unpredictable mutations and off-target effects, and applying them to Huntington's disease has limitations. In an attempt to address these issues, researchers employed Cas9 nickase, a more precise gene-editing enzyme that cuts a single strand of DNA within CAG/CTG sequences in mouse models of Huntington's disease.

When delivered to the striatum—the brain region primarily affected by the disease—using viral vectors, the therapy successfully shortened DNA repeats in most targeted neurons. This led to reduced toxic huntingtin protein aggregates, healthier gene expression pathways, and significant improvements in motor function. Crucially, no unwanted mutations were detected in brain cells using this approach, indicating a potentially safer alternative to conventional gene-editing methods.

While the study was based on mouse models and further research is required, the findings present an exciting new therapeutic pathway for Huntington's disease, which currently lacks a treatment that alters the disease course. The research, published in Science Translational Medicine, also highlights the potential for applying this approach to other genetic diseases caused by expanded repetitions in genetic codes.

Future work will focus on optimizing delivery methods, investigating the benefits of early-stage treatment, and conducting rigorous safety and efficiency testing in larger preclinical models to pave the way for potential human clinical trials.